Cap-dependent endonuclease inhibitors (CENis) - NHRC N0018926QB059
Summary
AI-generated · May 27, 2026Preclinical development of Cap-dependent endonuclease inhibitors (CENi), a class of small molecules with broad-spectrum antiviral activity.
Scope includes selecting lead CENi candidates, conducting in vitro and in vivo efficacy studies, and characterizing and optimizing lead compounds. It also requires research support expertise for preclinical development of CENis with viruses that require BSL-4 containment to support the Naval Medical Research Command in Fort Detrick, MD, over a 36-month period.
The preclinical development of Cap-dependent endonuclease inhibitors (CENi), a class of small molecules, as broad-spectrum antiviral therapeutics. The scope of this project includes all activities required to select lead CENi candidates, including in vitro and in vivo efficacy studies and characterization and optimization of lead compounds. This includes Research Support expertise regarding the preclinical development of cap-dependent endonuclease inhibitors (CENis) with viruses that require biosafety level 4 (BSL-4) containment to support the Naval Medical Research Command in Fort Detrick, MD. This work will be performed over a 36-month period.
From Combined Synopsis/Solicitation posted on May 26, 2026Notice history
1Details
Award Information
Not yet awarded
Contacts
Phone
Phone
Agency
Place of Performance
USA